# Study of rSIFN-co for Patients With Advanced Solid Tumors

> **NCT02464007** · PHASE1 · TERMINATED · sponsor: **Sichuan Huiyang Life Science and Technology Corporation** · enrollment: 7 (actual)

## Conditions studied

- Malignancies Including Melanoma, Kidney, Lung, Colorectal, Prostate, Neuroendocrine Tumor

## Interventions

- **BIOLOGICAL:** rSIFN-co

## Key facts

- **NCT ID:** NCT02464007
- **Lead sponsor:** Sichuan Huiyang Life Science and Technology Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2024-11
- **Final completion:** 2024-11
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Protocol has been amended and the Protocol amendment of Phase II was approved by the US FDA on Nov 2024 through SN0028.
- **Last updated:** 2025-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02464007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02464007, "Study of rSIFN-co for Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02464007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*